Business Wire

MA-ADVA

Share
UrsaNav trials eLoran as vital GNSS backup using ADVA’s grandmaster clock solution

ADVA (FSE: ADV) today announced that UrsaNav and ADVA have conducted an enhanced long-range navigation (eLoran) field trial using UrsaNav’s eLoran receiver and ADVA’s Oscilloquartz grandmaster clock technology. The successful demo shows that eLoran offers a robust and reliable backup for GPS and other GNSS and could be used to provide an assured position, navigation, and timing (PNT) service. The trial follows US federal executive order 13905 aimed at strengthening national resilience through PNT services, including protecting critical infrastructure such as electrical power grid and communication networks from rising cyber threats. By harnessing ADVA’s flexible OSA 5420 Series , designed with assured PNT (aPNT) technology, UrsaNav has shown that eLoran can provide a new layer of protection and significantly boost timing resilience and security.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005101/en/

“The success of this field trial demonstrates how eLoran, as part of ADVA’s assured PNT solution, can serve as a crucial backup for GPS. We have shown how our technology enables ADVA’s grandmaster clock to receive UTC timing from the eLoran system for a period of several days with the same accuracy and stability as GPS. Of course, this capability is extensible to other GNSS as well. eLoran is far less vulnerable to unintentional jamming and spoofing disruptions or intentional attacks, thereby delivering nanosecond precision with even more resilience,” said Charles Schue, CEO, UrsaNav. “By partnering with ADVA, we’ve been able to show that our eLoran receiver interoperates with the best network timing toolkit available. The OSA 5420 Series is a great product – highly efficient and easy to operate. Together with ADVA, we’re paving the way for tomorrow’s more robust assured PNT synchronization architecture.”

Across the globe, essential services and entire industries are increasingly reliant on GNSS for PNT information. But these satellite systems are inherently susceptible to interference, which could have disastrous consequences. A major disruption may result in billions of dollars of economic damage as well as a serious risk of loss of life. eLoran is one of the key technologies that could provide protection, with governments including the US exploring its potential as an alternative PNT source. UrsaNav’s latest trial harnessed the OSA 5420 Series grandmaster clock with inbuilt GNSS receiver. Timing stability from GPS was measured for several days. This was then replaced with eLoran for the same period with no loss of stability. What’s more, the test was conducted indoors where GNSS signals are not usually available, potentially extending the availability of precise UTC timing to many more environments.

“Commercially available GNSS jammers and spoofers are easy and cheap for attackers to construct. That’s part of the reason why we’re seeing a growing number of incidents across the world of blocked or misleading signals. If power utilities, enterprises, service providers and governments continue to rely on GNSS alone, it’s only a matter of time before the consequences become very serious. That’s why we’re committed to tackling GNSS vulnerabilities with advanced technologies like our ePRTC offering, cesium atomic clocks and our optical timing channel solution,” commented Nir Laufer, VP, product line management, Oscilloquartz, ADVA. “Now that UrsaNav has demonstrated the power of our OSA 5420 Series to utilize eLoran in the event of outages, we have another very important tool to ensure the quality and availability of time-sensitive services.”


About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About Oscilloquartz

Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .

About UrsaNav

Ursa Navigation Solutions (“UrsaNav”) is the world’s leading supplier of Low Frequency PNT solutions, with proven performance delivering the latest technology for eLoran systems, including transmission, control, monitoring, and reference site equipment. From initial concept through operational certification, UrsaNav provides every aspect of the provider or user experience, including commercial and military PNT solutions, critical infrastructure protection, and legacy system transformation. www.ursanav.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 318.9.2025 07:00:00 CEST | Press release

Curatis Holding AG (SIX:CURN) received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary t

Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay18.9.2025 07:00:00 CEST | Press release

Cetaphil's new Skin Activator Hydrating & Firming Line harnesses a proprietary formula, co-created with dermatologists and offering targeted, high-performance skincare designed to improve the appearance of skin affected by dermatoporosis The line’s new Skin Activator technology uses microdosed alpha hydroxy acid (AHA) and encapsulated centella asiatica (CICA) to wake up sleeping surface skin cells To help bring this segment-defining product line to life, Cetaphil is partnering with acclaimed actress, director, and advocate, Mariska Hargitay, a powerful voice in embracing beauty at every stage Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is redefining daily skincare with its new Skin Activator Hydrating & Firming line. The launch marks an entirely new skincare segment of advanced hydration and firming solutions designed specifically for improving the appearance of aging, thinning, and fragile skin. As people age, surface

Merck Opens Climate-Neutral €150 Million Filter Manufacturing Facility in Ireland18.9.2025 07:00:00 CEST | Press release

Part of company’s €440 million investment in Ireland, strengthens Merck’s in-region-for-region supply resilienceMerck’s first climate-neutral manufacturing facility, powered by 100 percent renewable electricityNew Blarney site in Cork, Ireland expands filter manufacturing capacity, creating more than 200 jobs by 2028 Merck, a leading science and technology company, has opened today its €150 million filter manufacturing facility in Blarney Business Park, Cork, Ireland. The site is Merck’s first manufacturing facility designed for full climate-neutral operations, marking a key milestone in the company’s ambition to achieve climate neutrality by 2040. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917767425/en/ Merck's new Blarney site in Cork expands company's filter capacity, creating 200+ jobs by 2028 The 3,000-square-meter cleanroom facility supports global demand for critical filtration products used in the manufacturin

Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)17.9.2025 21:46:00 CEST | Press release

Vimseltinib is the first and only therapy with marketing authorization for the treatment of TGCT in the European Union Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that the European Commission (EC) has approved ROMVIMZA™ (vimseltinib) in the European Union (EU) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with clinically relevant physical function deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability1. “The European Commission’s approval of vimseltinib for TGCT is a significant milestone for Deciphera, ONO, and TGCT patients across the European Union who are in need of a non-invasive treatment option. We are excited to leverage our global commercial infrastructure to bring vimseltinib to these patients,” said Ryota Udagawa, President and Chief Executive Officer of Deciphera. “We look forward to worki

Northern Escape Heli-Skiing Sees Global Surge in Demand as Adventurers Seek Canada’s Legendary Powder17.9.2025 18:09:00 CEST | Press release

Luxury adventure travel continues accelerating, with analysts projecting ~7.6% annual growth through 2030 [1][5]. Meanwhile, global tourism reached record highs in 2024 [2], and ski tourism is above pre-pandemic norms [3]. Northern Escape Heli-Skiing (NEH), named World’s Best Heli-Ski Operator by the World Ski Awards [4] in 2022, 2023, and 2024, continues to welcome a truly international mix of guests each winter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250909723150/en/ Global Appeal Post-pandemic travellers prioritize remote, nature-led adventures and privacy-forward itineraries [1][3]. Adventure tourism is on a sharp upswing globally [5], while research highlights how social media and influencer content accelerate demand for marquee mountain experiences [7]. At the same time, heli-sports are forecast to expand steadily across Canada, Europe, APAC, and South America [8]. World’s Best Heli-Ski NEH operates in BC’s Ske

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye